# Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

> **NCT00665990** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 49 (actual)

## Conditions studied

- Refractory Solid Tumors
- Leukemia

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Sorafenib
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00665990
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2015-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665990, "Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00665990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*